Trial Profile
A Phase 2, Multi-centeR, Randomized, DoUBle-Masked, Placebo-Controlled StudY to Evaluate the Clinical Safety and Efficacy of OKG-0301 in the Treatment of Acute Adenoviral Conjunctivitis
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Apr 2024
Price :
$35
*
At a glance
- Drugs Ranpirnase (Primary)
- Indications Viral-conjunctivitis
- Focus Therapeutic Use
- Acronyms RUBY
- Sponsors Okogen
- 20 Apr 2022 Planned End Date changed from 30 Jun 2021 to 30 Jun 2022.
- 20 Apr 2022 Planned primary completion date changed from 30 Jun 2021 to 30 Jun 2022.
- 29 Apr 2021 According to an Okogen media release, data from this trial will be presented by Professor Stephanie Watson in greater detail at the ARVO virtual annual meeting, May 1-7, 2021.